Posts by Replicor
Replicor updates NAP development with seven presentations at the 2017 International HBV Meeting
MONTREAL, September 12, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announced today availability on its website of all seven presentations made at the 2017 International Meeting on The Molecular Biology of Hepatitis B Viruses…
Read MoreSix Replicor presentations to be featured at the 2017 International HBV Meeting
MONTREAL, August 28, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announced today the acceptance of six abstracts for presentation at the 2017 International Meeting on The Molecular Biology of Hepatitis B Viruses being held…
Read MoreReplicor announces publication of its studies on the antiviral activity of NAPs in recognized in vitro models of HBV infection
MONTREAL, June 28, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announced today the publication of its study on the activity of NAPs in recognized in vitro models of HBV infection in the journal PLOS ONE. (http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0179697&type=printable).…
Read MoreReplicor announces publication of pre-clinical safety and pharmacokinetic data on NAPs
MONTREAL, June 12, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announced today the publication of its study on the preclinical evaluation of its clinical NAP candidates REP 2139 and REP 2165 in the journal…
Read MoreReplicor discloses achievement of 1 year functional control of HBV and HDV with NAPs and new mechanistic insights in NAP pharmacology
MONTREAL, April 20, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic HBV and HDV infection, today disclosed significant new data on NAP activity in HBV and HDV infections at the European Association for the Study of the Liver (EASL) 2017 annual meeting held April 19-23, 2017 in Amsterdam, The Netherlands.…
Read MoreReplicor to Make Five Presentations at EASL 2017
MONTREAL, April 3, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D infection, today announced that the European Association for the Study of the Liver (EASL) selection committee has accepted five Replicor abstracts for presentation at the EASL 2017 annual meeting to be held April 19-23, 2017…
Read MoreReplicor announces publication of study showing NAPs do not directly stimulate the immune response
MONTREAL, March 23, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announces the publication of its study on the immunostimulatory properties of its nucleic acid polymer (NAP technology) in the journal Scientific Reports (http://www.nature.com/articles/srep43838?WT.feed_name=subjects_immunology). This…
Read MoreReplicor discloses high rates of HBsAg loss with NAP combination therapy at APASL 2017
MONTREAL, Feb 20, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, presented an updated interim analysis from its latest REP 401 clinical trial at the Asia Pacific Association for the Study of Liver (APASL) held February 15-19, 2017 in Shanghai, China. The REP 401…
Read MoreReplicor discloses updated REP 401 clinical data at APASL 2017
MONTREAL, Feb 10, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that an updated interim analysis from its latest REP 401 clinical trial has been selected by the Asia Pacific Association for the Study of Liver (APASL) for oral presentation at its…
Read MoreReplicor discloses late breaking HBV and follow-up HBV / HDV clinical data at AASLD 2016
MONTREAL, Nov 15, 2016 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today presented its preliminary interim analysis from its latest REP 401 clinical trial at the American Association for the Study of Liver Disease (AASLD) during the late-breaking oral abstract session at its annual…
Read More